Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Recurrence 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Oxaliplatin 14sintilimab 10S 1 (combination) 9Drug Therapy 7Capecitabine 5tislelizumab 4Surgical Procedures, Operative 4Paclitaxel 4HMPL-013 4apatinib 3Tegafur 3Immune Checkpoint Inhibitors 3Cisplatin 3Bevacizumab 3surufatinib 2potassium oxonate 2lenvatinib 2irinotecan sucrosofate 2gimeracil 2Observation 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorouracil 2Exercise 2Endoscopic Mucosal Resection 2Doxorubicin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zolbetuximab 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Stomach Neoplasms × Pharmaceutical Preparations × Clear all
NCT07364422 2026-01-23

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Onconic Therapeutics Inc.

Phase 1/2 Not yet recruiting
49 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡